Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?

"CONFLICT OF INTERESTS C. K., V. T., and K. D. have nothing to declare. E. R. participated in advisory boards for Roche, Bristol‐Myers Squibb, and AstraZeneca. M. J. L. L. is consultant in advisory boards for AstraZeneca, Bayer, Janssen Pharmaceuticals, Merck, Nimagen, Roche, and received financial support from AstraZeneca and Bristol‐Myers Squibb (all fees to the institute). E. S. performed lectures for Illumina, Novartis, Pfizer, BioCartis; is consultant in advisory boards for AstraZeneca, Pfizer, Novartis, BioCartis; and received financial support from Roche, Biocartis, Bristol‐Myers Squibb, and Pfizer (all fees to the institute). E. M. C. D. received an unrestricted research grant from Pfizer Oncology to support the organization of the ESP Lung EQA schemes."

"FUNDING An unrestricted research grant from Pfizer Oncology was received by EMCD for the organization of the ESP Lung EQA schemes, irrespective of the research performed during this study."